Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 vs Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
NCT07894211Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Mar 2029
01
Overview
A Phase 3 trial of MHB088C in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Qilu Pharmaceutical. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
MHB088C
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07894211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894211.